Literature DB >> 30421549

Management of oral mucositis in pediatric patients receiving cancer therapy: A systematic review and meta-analysis.

Fatemeh Mazhari1,2, Alireza Sarraf Shirazi3,4, Mahboubeh Shabzendehdar5.   

Abstract

BACKGROUND: One of the most common complications of cancer chemotherapy is oral mucositis (OM). OM affects more than 75% of patients undergoing chemotherapy and represents a significant burden to patients and caregivers. We performed a systematic review and meta-analysis of published studies to investigate the effects of agents and techniques in reducing OM. PROCEDURE: This systematic review investigated, critically appraised, and rated the evidence on agents used to manage OM in children undergoing cancer therapy. A comprehensive search of the relevant literature was performed from January 2006 to December 2017. MEDLINE, Scopus, the Cochrane Database of Systematic Reviews, EMBASE, and the Web of Science were searched. Nine eligible studies were identified. Using random-effects models, standardized mean difference was estimated between treated and control groups across all studies. The Cochran test and the I2 index were performed for heterogeneity between studies. The significance level was set at P = 0.05.
RESULTS: Palifermin reduced the incidence (OR = 4.131, P = 0.000), duration (St diff mean = 0.803, P = 0.000), and severity (St diff mean = 0.637, P = 0.000) of OM in pediatric cancer patients significantly. However, the laser did not show significant efficacy in decreasing the incidence rate of OM (OR = 2.870, P = 0.364).
CONCLUSION: This review provided a comprehensive examination of available options for children who have OM. The results support the possibility of a positive effect of palifermin on reducing OM in children receiving cancer therapy.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  cancer therapy; children; oral mucositis

Mesh:

Substances:

Year:  2018        PMID: 30421549     DOI: 10.1002/pbc.27403

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  6 in total

1.  Incidence and risk factors for oral mucositis in pediatric patients receiving chemotherapy.

Authors:  Marina Curra; Amanda F Gabriel; Maria Beatriz C Ferreira; Marco Antonio T Martins; André T Brunetto; Lauro J Gregianin; Manoela Domingues Martins
Journal:  Support Care Cancer       Date:  2021-04-12       Impact factor: 3.603

Review 2.  Oral Microbiota during Childhood and Its Role in Chemotherapy-Induced Oral Mucositis in Children with Cancer.

Authors:  Silvia Triarico; Pierpaolo Agresti; Emanuele Rinninella; Maria Cristina Mele; Alberto Romano; Giorgio Attinà; Palma Maurizi; Stefano Mastrangelo; Antonio Ruggiero
Journal:  Pathogens       Date:  2022-04-07

3.  MASCC/ISOO clinical practice guidelines for the management of mucositis: sub-analysis of current interventions for the management of oral mucositis in pediatric cancer patients.

Authors:  Wanessa Miranda-Silva; Wagner Gomes-Silva; Yehuda Zadik; Noam Yarom; Abdul Rahman Al-Azri; Catherine H L Hong; Anura Ariyawardana; Deborah P Saunders; M Elvira Correa; Praveen R Arany; Joanne Bowen; Karis Kin Fong Cheng; Wim J E Tissing; Paolo Bossi; Sharon Elad
Journal:  Support Care Cancer       Date:  2020-11-06       Impact factor: 3.603

4.  Palifermin as primary mucositis prophylaxis in patients with B-cell Non-Hodgkin lymphoma: a case series.

Authors:  Anthony S Zembillas; Stefanie M Thomas; Seth J Rotz; Ilia N Buhtoiarov; Rabi Hanna
Journal:  Pediatr Hematol Oncol       Date:  2021-05-18       Impact factor: 1.969

5.  Herb medicine for relieving radiation induced oral mucositis: A systematic review and meta-analysis protocol.

Authors:  Gui Wang; Liqun Jia
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.817

6.  Comparison of Side Effects of Nalbuphine and Morphine in the Treatment of Pain in children with Cancer: A Prospective Study.

Authors:  Anna Kubica-Cielińska; Michał Czapla; Raúl Juárez-Vela; Clara Isabel Tejada-Garrido; Marzena Zielińska
Journal:  Cancers (Basel)       Date:  2022-07-25       Impact factor: 6.575

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.